Literature DB >> 11224327

The effects of selective and non-selective monoamine oxidase (MAO) inhibitors on conflict behavior in the rat.

R.L. Commissaris1, J. Humrich, J. Johns, D.G. Geere, D.J. Fontana.   

Abstract

Conflict behavior in rats was examined over the course of several weeks of chronic treatment with selective and non-selective monoamine oxidase inhibitors (MAOIs). In daily 10min sessions, rats were trained to drink from a tube which was occasionally electrified (0.5mA). Electrification was signalled by the presence of a tone. Within 3-4 weeks, control (i.e. non-drug) conflict behavior had stabilized (30-40 shocks and 8-12ml water/session) and drug testing began. Chronic administration (two injections/day for 8 weeks) with a non-selective (i.e. MAO-A and MAO-B inhibiting) dose of pargyline (15mg/kg) resulted in a time-dependent increase in punished responding. In contrast, chronic administration of the MAO-A selective inhibitor (clorgyline; 1.0mg/kg, 2mg/kg), the MAO-B selective inhibitor deprenyl (5mg/kg) or MAO-B inhibiting doses of pargyline (1.0mg/kg, 5mg/kg) were without effect. Finally, chronic treatment with the combination of a low dose of clorgyline (1.0mg/kg) and a low dose of pargyline (1.0mg/kg) did result in a time-dependent increase in punished responding. These results suggest that inhibition of both MAO-A and MAO-B is required for the eventuation of the anxiolytic effect resulting from chronic MAOI treatment.

Entities:  

Year:  1995        PMID: 11224327

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  2 in total

1.  The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA.

Authors:  T Paslawski; D Treit; G B Baker; M George; R T Coutts
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

2.  Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice.

Authors:  Marco Bortolato; Sean C Godar; Shieva Davarian; Kevin Chen; Jean C Shih
Journal:  Neuropsychopharmacology       Date:  2009-08-26       Impact factor: 7.853

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.